Lenvatinib is a multikinase inhibitor which mainly hinders liver cancer proliferation by
inhibiting angiogenesis. In 2018, Lenvatinib was approved for the first-line treatment of …

Various cancer therapies have advanced remarkably over the past decade. Unlike the direct
therapeutic targeting of tumor cells, cancer immunotherapy is a new strategy that boosts the …

Nucleotide binding oligomerization domain 2 (NOD2) is a recognized innate immune sensor
which can initiate potent immune response against pathogens. Many innate immune …

A major limitation of immunotherapy is the development of resistance resulting from cancer-
mediated inhibition of host lymphocytes. Cancer cells release CCL2 to recruit classical …

Cancer is a serious threat to humans due to its high mortality. The efforts to fully understand
cancer and to fight against it have never been stopped. The traditional therapies, such as …

Simple Summary Bone sarcomas are rare cancers coming from the mesenchyme cells of the
body skeletal system. Osteosarcoma, chondrosarcoma, Ewing sarcoma, and chordoma are …

Nucleotide-binding oligomerization domain 2 (NOD2) is a receptor of the innate immune
system that is capable of perceiving bacterial and viral infections. Muramyl dipeptide (MDP …

We report on the design, synthesis, and biological evaluation of a series of nucleotide-
binding oligomerization-domain-containing protein 2 (NOD2) desmuramylpeptide agonists …

In bacteria, the cell envelope is the key element surrounding and protecting the bacterial
content from mechanical or osmotic damages. It allows the selective interchanges of solutes …

The innate immune receptor nucleotide-binding oligomerization-domain-containing protein
2 (NOD2) represents an important target for the development of structurally defined small …